Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Latest Information Update: 09 Jan 2024
Price :
$35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 26 Jun 2023 Results (n=6) assessing effects of SGLT2i on cardiopulmonary function measured by cardiopulmonary exercise test & 6MWT in patients with T2D & HFrEF presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 14 Feb 2023 Planned End Date changed from 1 Feb 2025 to 31 Mar 2027.
- 14 Feb 2023 Planned primary completion date changed from 1 Oct 2024 to 30 Nov 2026.